According to Zhitong Finance APP, CHINARES PHARMA (03320) announced that during the period from November 8, 2024, to December 18, 2024, the company's wholly-owned subsidiary, CHINARES PHARMA Investment, has cumulatively acquired approximately 6.4246 million shares of Dong-E-E-Jiao through the centralized auction trading system of the Shenzhen Stock Exchange (accounting for 1.00% of Dong-E-E-Jiao's total share capital, excluding shares repurchased by Dong-E-E-Jiao held in designated accounts).

As of the date of this announcement and after the aforementioned shareholding increase, Dong-E-E-Jiao is held approximately 10.02% by CHINARES PHARMA Investment and about 23.56% by the company through its non-wholly-owned subsidiary, CHINARES Dong-E-E-Jiao Co., Ltd., and the group effectively controls approximately 33.58% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the company.